José L Salgado

TL;DR: Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control and, most importantly, markedly diminished occurrence of major CVD events.

TL;DR: Asleep systolic blood pressure (SBP) mean was the most significant BP-derived risk factor for the primary outcome and treatment-induced decrease of asleep, but not awake SBP, a novel hypertension therapeutic target requiring periodic patient evaluation by ambulatory monitoring, is associated with significantly lower risk for CVD morbidity and mortality.

TL;DR: Investigating the influence of hypertension treatment-time regimen on the circadian BP pattern, degree of BP control, and relevant clinical and analytical parameters of hypertensive patients with type 2 diabetes indicated that bedtime hypertension treatment, in conjunction with proper patient evaluation by ABPM, should corroborate the diagnosis of hypertension and avoid treatment-induced nocturnal hypotension.

TL;DR: These collective findings reveal important limitations of CVD risk stratification when based upon OBPM, as in the Framingham score, and corroborate the clinical value of around-the-clock ABPM to properly diagnose true hypertension and reliably stratify CVD vulnerability.

TL;DR: Los resultados documentan importantes limitaciones of the estratificacion del riesgo of ECV basada en MCPA, incluidas las del modelo de Framingham, y corroboran el valor of the MAPA para diagnosticar hipertension y estratIFICar el riesgos de ECV.